F10 and neoplasm: An FXa inhibitor, rivaroxaban, did not directly affect the growth of TF-positive pancreatic cancer xenografts in immunodeficient mice [194], but did suppress tumor growth in an immunocompetent setting that was partially dependent on reprograming tumor-associated macrophages [195].